MULTIMEDIA ADDITION Capri EGM acquires R&D; Build-to-Suit for National Resilience, a biomanufacturing company under contract with DOD, Harvard and Moderna
CHICAGO, February 25, 2022–(BUSINESS WIRE)–Capri EGM, an investment firm specializing in the financing of bespoke construction and corporate sale-leaseback and the acquisition of income-generating real estate in the areas of life sciences, R&D; and of logistics, financed and acquired a state-of-the-art new construction. laboratory and R&D; facility for National Resilience Inc. (Resilience), a technology-driven biomanufacturing company dedicated to expanding access to complex medicines and protecting biopharmaceutical supply chains from disruption.
This press release is multimedia. Read the full press release here: https://www.businesswire.com/news/home/20220224006137/en/
Resilience’s laboratory and research facilities are adjacent to its manufacturing facility in Alachua, Florida, where it will develop a monoclonal antibody for the US Department of Defense. (Photo: BusinessWire)
Ology Bioservices, a wholly owned subsidiary of Resilience, and the operator of the laboratory and research facility, was recently awarded a contract valued at $250 million by the Department of Defense for the development of manufacturing of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT). Resilience also entered into a multi-year agreement to produce mNRAs for Moderna’s Covid-19 vaccine, a multi-year strategic R&D; alliance with Harvard University to develop complex drugs, and a multi-product biomanufacturing development agreement with Takeda to support their portfolio of plasma-derived medicines. .
The bespoke Resilience and Research Lab is strategically located in the North Florida Life Sciences and Research Cluster near the University of Florida and the University of Florida’s Innovate Sid Martin Biotech Incubator. Florida, the world’s #1 ranked biotech incubator. The property is surrounded by a variety of other high-tech symbiotic uses, including bioscience and medical product development, pharmaceutical compounding, and R&D; businesses. Proximity to the University of Florida, a top 5 public university, provides a pool of talent and research opportunities.
Capri EGM confirms that life sciences and R&D; corporate real estate remain high conviction themes for its bespoke build program and ongoing investment activity and believes that these types of assets are among the greatest beneficiaries of developing macroeconomic trends. Life sciences real estate capital markets activity set an all-time high in 2021, with investment volumes of $18.4 billion according to Newmark. Capri EGM believes the pandemic has only increased the need for these types of assets and underscored their importance. As Capri EGM looks to current investments, innovation-driven markets with leading research universities will remain areas of focus for its investment activity, as it believes these markets will continue to make the subject to strong demand from companies wishing to participate in their local ecosystems.
National Resilience is a technology-driven manufacturing company dedicated to expanding access to complex medicines and protecting biopharmaceutical supply chains from disruption. The company is building a sustainable network of end-to-end high-tech manufacturing solutions to ensure the drugs of today and tomorrow can be manufactured quickly, safely and at scale. By continually advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on discoveries that improve the lives of patients.
Portfolio management company comments
Shelby EL Pruett, CEO of Capri EGM, said: “The Covid-19 pandemic has highlighted the need to protect our biopharmaceutical and global supply chains from disruption and to strengthen our country’s ability to manufacture products. pharmaceuticals and to develop treatments for potential future health risks. is a company on a mission to achieve these goals and we are pleased to help meet their infrastructure needs through the funding and acquisition of this bespoke facility. Life Sciences, R&D; and Logistics-related real estate remain high-conviction themes for our ongoing bespoke construction and investment programs, as we believe these types of assets will be among the biggest beneficiaries of developing macroeconomic trends.”
Capri EGM
Capri EGM is an established real estate investment firm specializing in the financing of bespoke construction and corporate sale-leaseback and the acquisition of income-generating corporate real estate in the areas of logistics, life sciences and R&D; in high-growth markets across the United States. Since 1992, the Capri EGM management team and its predecessors have acquired, originated and managed over $10 billion in commercial real estate investments directly and through entity-level investments. Please visit capri-egm.com for more information on Capri EGM.
This press release contains forward-looking statements within the meaning of the federal securities laws. Mr. Pruett’s comments and statements regarding the acquisition of the National Resilience facility or characteristics of the property are examples of forward-looking statements. This announcement does not constitute an offer to sell or a solicitation of an offer to buy any security relating to Capri EGM or any of its entities’ funds or investment vehicles. Any offer or solicitation may only be made by the delivery of a definitive private offering memorandum and all information contained therein is qualified in its entirety by such memorandum.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220224006137/en/
contacts
Capri EGM Media Contacts:
Jeff Fisher 312-805-4850